ENZO BIOCHEM TO PROVIDE ACCESS TO COVID-19 TESTING AT MORE THAN 50 NY PHARMACIES IN COLLABORATION WITH CPESN NY
21 July 2020 - 10:30PM
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostic
company, and Community Pharmacy Enhanced Services Network (CPESN®
NY), the New York division of the clinically integrated, nationwide
organization of pharmacy networks, announced today they are
partnering to provide COVID-19 testing at 52 of the network’s 155
pharmacies across New York State. This initial pilot was made
possible in strong collaboration with Pharmacists’ Society of the
State of New York (PSSNY). “This program aligns with our goal to
promote the strong relationship between independent pharmacies and
patients in their communities by addressing needs related to
COVID-19 testing, one of the most important health challenges in a
generation,” said CPESN Facilitator Chris Daly. “This program will
bring easy access to testing to more New Yorkers through a health
resource that they know and trust, with the ability to provide
faster turnaround times and results.”
“Enzo is providing effective testing solutions for many schools
and other institutions through our School and Institution Testing
(“SIT”) Program, and to New York-based nursing homes through a
collaboration with the State of New York. This new testing program
with independent pharmacies is the next step in our goal of being
the leading provider of easy-access testing products and services
throughout our region,” said Barry Weiner, President of Enzo.
“As this pandemic continues to escalate, even in areas where we
have made positive progress, large-scale testing is a critical
component of keeping people safe and informed and stopping the
spread of COVID-19.”
Through this program, the Enzo Center of Excellence will provide
the high-level products and services to support effective testing
in locations across the State. Relying on over 40 years of research
and manufacturing expertise, Enzo’s emergency use authorized (EUA)
AMPIPROBE® SARS-CoV-2 swab molecular test is manufactured at its
Farmingdale, New York GMP facility with state of the art technology
for use in Enzo’s own CLIA-certified (high complexity) clinical
laboratory and distribution to other authorized clinical
laboratories.
Through this program, NY residents will have access to testing
at participating independent pharmacies beginning
immediately. Enzo provides the full range of services to
support rapid and accurate testing, including reagent manufacturing
capabilities, proprietary diagnostic instruments, and clinical
laboratory services. Results from the swab test should be
provided within two to three days from sample collection.
Patients will also have access to guidance and information from the
leading independent pharmacies participating in this program.
Enzo Clinical Labs is a New York State Department of
Health-regulated, full-service clinical reference laboratory
serving the needs of patients and other clinical laboratories in
the region.
Enzo diagnostic and laboratory services are backed by extensive
data and research. A white paper titled “Enzo’s Emergency Use
Authorized AMPIPROBE® SARS-CoV-2 Test System” is currently
available on the ENZO website at https://www.enzo.com/coronavirus,
along with two previously published white papers detailing Enzo’s
COVID-19 Product and Platform.
About Enzo Biochem Enzo
Biochem is a pioneer in molecular diagnostics, leading the
convergence of clinical laboratories, life sciences and
intellectual property through the development of unique diagnostic
platform technologies that provide numerous advantages over
previous standards. A global company, Enzo Biochem utilizes
cross-functional teams to develop and deploy products, systems and
services that meet the ever-changing and rapidly growing needs of
health care today and into the future. Underpinning Enzo Biochem’s
products and technologies is a broad and deep intellectual property
portfolio, with patent coverage across a number of key enabling
technologies.
About CPESN® USA
CPESN® USA a clinically integrated, nationwide
organization of pharmacy networks structured to advance
community-based pharmacy practice. They empower community-based
pharmacies that are deeply rooted within their community by
fostering their ability to provide high quality, patient-centered
enhanced services. CPESN® pharmacies integrate with the other
providers on the patient’s care team and coordinate medical
treatment, which has led to better medication adherence, higher
patient satisfaction, and lower healthcare costs. You can now find
CPESN® Networks of pharmacy providers in 45 states across America.
To learn more, please visit http://www.cpesn.com/.
About PSSNY
The Pharmacists Society of the State of New York
(PSSNY), a not-for-profit incorporated society, represents
pharmacists in all practice settings and is the largest pharmacy
association in New York State. In addition to legislative advocacy,
PSSNY provides pharmacists, pharmacy owners, students and faculty
with educational programming, interprofessional collaboration and a
statewide voice for professional and practice matters. A membership
organization founded in 1879, PSSNY has a diverse and active
membership, and opportunities for corporate and community
involvement.
Forward-Looking Statements
Except for historical information, the matters
discussed in this release may be considered "forward-looking"
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended and Section 21E of the Securities Exchange Act
of 1934, as amended. Such statements include declarations regarding
the intent, belief or current expectations of the Company and its
management, including those related to cash flow, gross margins,
revenues, and expenses which are dependent on a number of factors
outside of the control of the Company including, inter alia, the
markets for the Company’s products and services, costs of goods and
services, other expenses, government regulations, litigation, and
general business conditions. See Risk Factors in the Company’s Form
10-K for the fiscal year ended July 31, 2019. Investors are
cautioned that any such forward-looking statements are not
guarantees of future performance and involve a number of risks and
uncertainties that could materially affect actual results. The
Company disclaims any obligations to update any forward-looking
statement as a result of developments occurring after the date of
this release.
###
Contact:
For Enzo Biochem, Inc.
David Bench, CFO 212-583-0100 dbench@enzo.com
For CPESN NY, LLC
Chris Daly, Network Facilitator, CPESN NY, LLC
cdaly@cpesn.com
Media:
Lynn GranitoBerry & Company Public
Relations973-818-3732lgranito@berrypr.com
Investors:
Melanie SolomonThe Blueshirt
Group415-217-4964melanie@blueshirtgroup.com
Steve AnrederAnreder &
Company212-532-3232Steven.anreder@anreder.com
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Apr 2024 to May 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From May 2023 to May 2024